These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Thiopurine therapy in inflammatory bowel disease in the pandemic era: Safe or unsafe? Perdalkar S; Basthi Mohan P; Musunuri B; Rajpurohit S; Shetty S; Bhat K; Pai CG Int Immunopharmacol; 2023 Mar; 116():109597. PubMed ID: 36702073 [TBL] [Abstract][Full Text] [Related]
3. The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic. Kamath C; Brenner EJ Curr Res Pharmacol Drug Discov; 2022; 3():100101. PubMed ID: 35496814 [TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N; Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954 [TBL] [Abstract][Full Text] [Related]
5. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Lin S; Lau LH; Chanchlani N; Kennedy NA; Ng SC Gut; 2022 Jul; 71(7):1426-1439. PubMed ID: 35477864 [TBL] [Abstract][Full Text] [Related]
6. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients. Caldera F; Saha S; Wald A; Garmoe CA; McCrone S; Megna B; Ley D; Reichelderfer M; Hayney MS Dig Dis Sci; 2018 Jun; 63(6):1532-1540. PubMed ID: 29594970 [TBL] [Abstract][Full Text] [Related]
7. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection? Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059 [TBL] [Abstract][Full Text] [Related]
8. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19. Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102 [TBL] [Abstract][Full Text] [Related]
9. Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives. Suria C; Bosca-Watts MM; Navarro P; Tosca J; Anton R; Sanahuja A; Revaliente M; Minguez M Gastroenterol Hepatol; 2022 May; 45(5):383-389. PubMed ID: 34171421 [TBL] [Abstract][Full Text] [Related]
10. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. El Ouali S; Rubin DT; Cohen BL; Regueiro MD; Rieder F Curr Opin Gastroenterol; 2021 Jul; 37(4):313-319. PubMed ID: 33859104 [TBL] [Abstract][Full Text] [Related]
11. Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease. Long MD; Parlett L; Lewis JD; Haynes K; Adimadhyam S; Hou L; Wolfe A; Toh S; Burris J; Dorand J; Kappelman MD Inflamm Bowel Dis; 2024 Aug; 30(8):1345-1352. PubMed ID: 37611117 [TBL] [Abstract][Full Text] [Related]
12. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. Meyer A; Semenzato L; Zureik M; Weill A; Carbonnel F; Dray-Spira R Aliment Pharmacol Ther; 2021 Jul; 54(2):160-166. PubMed ID: 34110040 [TBL] [Abstract][Full Text] [Related]
13. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD. Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385 [TBL] [Abstract][Full Text] [Related]
14. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234 [TBL] [Abstract][Full Text] [Related]
15. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S; Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009 [TBL] [Abstract][Full Text] [Related]
16. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination. Caldera F; Farraye FA; Necela BM; Cogen D; Saha S; Wald A; Daoud ND; Chun K; Grimes I; Lutz M; Van Helden SR; Swift MD; Virk A; Bharucha AE; Patel TC; Gores GJ; Chumsri S; Hayney MS; Knutson KL Inflamm Bowel Dis; 2023 Aug; 29(8):1202-1209. PubMed ID: 36103273 [TBL] [Abstract][Full Text] [Related]
17. Effects of COVID-19 on Patients with Inflammatory Bowel Disease. Kogan L; Ungaro RC; Caldera F; Shah SA R I Med J (2013); 2022 Dec; 105(10):42-47. PubMed ID: 36413451 [TBL] [Abstract][Full Text] [Related]
18. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626 [TBL] [Abstract][Full Text] [Related]
19. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study. Liu Z; Alexander JL; Le K; Zhou X; Ibraheim H; Anandabaskaran S; Saifuddin A; Lin KW; McFarlane LR; Constable L; Seoane RC; Anand N; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HR; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N; EClinicalMedicine; 2023 Oct; 64():102249. PubMed ID: 37842172 [TBL] [Abstract][Full Text] [Related]
20. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]